What is the 13F Pro Quality Score for ATNM?

13F Pro ranks Actinium Pharmaceuticals, Inc. (ATNM) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ATNM's current score at https://13fpro.ai/company/ATNM (free sign-up required for the full ranking).

Where does 13F Pro source ATNM data?

All Actinium Pharmaceuticals, Inc. fundamentals and ownership data come directly from SEC EDGAR. Actinium Pharmaceuticals, Inc. files with the SEC under CIK 1388320. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ATNM in?

Actinium Pharmaceuticals, Inc. (ATNM) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ATNM research updated on 13F Pro?

ATNM's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Actinium Pharmaceuticals, Inc.(ATNM)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSEsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1388320 ATNM stock profile & AI dashboard →

13F Pro Quality Score

36.5/100

Rank #2,266 of 2,961 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why ATNM Scores 37/100

exact factor attribution · 2026-09-11

ATNM's composite is driven by revenue growth and capital efficiency, held back by free cash flow and profitability. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+9.3 pts

97th pct

Capital efficiency

+4.7 pts

97th pct

Earnings growth

-1.0 pts

30th pct

Institutional flow

-1.3 pts

23th pct

Shareholder dilution

-2.5 pts

1th pct

Scale

-3.0 pts

30th pct

Earnings quality

-4.9 pts

1th pct

Profitability

-7.4 pts

1th pct

Free cash flow

-7.4 pts

1th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

ATNM Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Actinium Pharmaceuticals, Inc. (ATNM), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ATNM at 36.5/100 on a 32-signal composite quality model, placing it at rank #2,266 of 2,961 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), Actinium Pharmaceuticals, Inc. reports quarterly revenue of $35.0M, net income of $27.9M, an operating margin of 78.8%. Top institutional holders of ATNM by reported 13-F value include VANGUARD CAPITAL MANAGEMENT, COMPASS FINANCIAL MANAGEMENT, MILLENNIUM MANAGEMENT, based on the most recent SEC filings. ATNM trades on the NYSE exchange and files with the SEC under CIK 1388320. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ATNM daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Actinium Pharmaceuticals, Inc. directly from SEC EDGAR. Actinium Pharmaceuticals, Inc.'s 13F Pro composite quality score has ranged between 6 and 38 since 2023, currently 36.5 — an improving long-term trajectory across 12 quarterly and live scoring snapshots.

Revenue

Q2 2026

$35.0M

Net Income

Q2 2026

$27.9M

Free Cash Flow

Q2 2026

$-5.7M

Operating Margin

Q2 2026

78.8%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

$90.0KFY 2025

FY22 $1.0MFY23 $81.0KFY24 —FY25 $90.0K

Net Income

+11.4% YoY

$-33.9MFY 2025

FY22 $-33.0MFY23 $-48.8MFY24 $-38.2MFY25 $-33.9M

Operating Income

+13.9% YoY

$-36.2MFY 2025

FY22 $-34.1MFY23 $-51.9MFY24 $-42.1MFY25 $-36.2M

EPS (Diluted)

+14.2% YoY

$-1.09FY 2025

FY22 $-1.37FY23 $-1.83FY24 $-1.27FY25 $-1.09

Total Assets

-32.7% YoY

$51.8MFY 2025

FY22 $114.2MFY23 $81.4MFY24 $76.9MFY25 $51.8M

Op. Cash Flow

+25.7% YoY

$-24.6MFY 2025

FY22 $8.6MFY23 $-47.3MFY24 $-33.1MFY25 $-24.6M

Free Cash Flow

+25.4% YoY

$-24.7MFY 2025

FY22 $8.3MFY23 $-47.5MFY24 $-33.1MFY25 $-24.7M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$90.0K	—	$81.0K -92.1%	$1.0M -10.0%	$1.1M	—
Net Income	$-33.9M +11.4%	$-38.2M +21.7%	$-48.8M -47.9%	$-33.0M -33.3%	$-24.8M -11.5%	$-22.2M
Operating Income	$-36.2M +13.9%	$-42.1M +18.9%	$-51.9M -52.2%	$-34.1M -36.6%	$-25.0M -11.5%	$-22.4M
EPS (Diluted)	$-1.09 +14.2%	$-1.27 +30.6%	$-1.83 -33.6%	$-1.37 -14.2%	$-1.20	—
Total Assets	$51.8M -32.7%	$76.9M -5.6%	$81.4M -28.7%	$114.2M +42.1%	$80.4M +21.1%	$66.4M
Operating Cash Flow	$-24.6M +25.7%	$-33.1M +30.1%	$-47.3M -647.6%	$8.6M +141.4%	$-20.9M +3.5%	$-21.6M
Free Cash Flow	$-24.7M +25.4%	$-33.1M +30.3%	$-47.5M -673.7%	$8.3M +139.4%	$-21.0M +4.0%	$-21.9M

Get alerted when ATNM's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Actinium Pharmaceuticals, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ATNM

VANGUARD CAPITAL MANAGEMENT LLC
$1.2M1,238,302 sh
COMPASS FINANCIAL MANAGEMENT LLC
$588.2K600,230 sh
MILLENNIUM MANAGEMENT LLC
$504.3K514,580 sh
ACADIAN ASSET MANAGEMENT LLC
$485.0K496,288 sh
BlackRock, Inc.
$388.0K395,896 sh
RENAISSANCE TECHNOLOGIES LLC
$372.9K380,491 sh
GEODE CAPITAL MANAGEMENT, LLC
$318.6K324,945 sh
TWO SIGMA INVESTMENTS, LP
$254.0K259,179 sh
GAGNON SECURITIES LLC
$178.5K182,142 sh
VANGUARD FIDUCIARY TRUST CO
$158.3K161,526 sh

Fund	Value	Shares
VANGUARD CAPITAL MANAGEMENT LLC	$1.2M	1,238,302
COMPASS FINANCIAL MANAGEMENT LLC	$588.2K	600,230
MILLENNIUM MANAGEMENT LLC	$504.3K	514,580
ACADIAN ASSET MANAGEMENT LLC	$485.0K	496,288
BlackRock, Inc.	$388.0K	395,896
RENAISSANCE TECHNOLOGIES LLC	$372.9K	380,491
GEODE CAPITAL MANAGEMENT, LLC	$318.6K	324,945
TWO SIGMA INVESTMENTS, LP	$254.0K	259,179
GAGNON SECURITIES LLC	$178.5K	182,142
VANGUARD FIDUCIARY TRUST CO	$158.3K	161,526

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ATNM on your watchlist

Track score changes the day Actinium Pharmaceuticals, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ATNM a good stock to buy?

13F Pro's AI-powered analysis of Actinium Pharmaceuticals, Inc. (ATNM) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ATNM are available on the ATNM stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. ATNM is classified as a small company.

Which hedge funds own ATNM?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ATNM. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Actinium Pharmaceuticals, Inc.'s investment landscape.